Search Medical Condition
Please enter condition
Please choose location from dropdown

Depression (Treatment-Resistant) Clinical Trials

A listing of Depression (Treatment-Resistant) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (69) clinical trials

Structural and Functional Connectivity of Brainstem Monoamine Pathways in Treatment Resistant Depression

Potential subjects will be identified during clinical visits. If a patient qualifies to participate in the study they will have to stop any antidepressants that they are taking to prepare for the use of MAOIs. After a two week washout period, subjects will have an fMRI and will be started ...

Phase N/A

Personalized rTMS for Resistant Depression

The investigators hypothesize that personalizing the rTMS targets using functional MRI will increase its efficacy. The most dysfunctional regions or the most dysfunctional network will be stimulated homogeneously. Individualized rTMS will be compared to traditional rTMS procedure and to trans-cranial direct current stimulation (tDCS) in a randomized cross-over trial. In ...

Phase N/A

Deep Brain Stimulation of the Bilateral Habenula for Treatment- Resistant Major Depression

Several open-label trials have shown the therapeutic promise of deep brain stimulation (DBS) in treatment-resistant depression (TRD). However, the results of placebo-controlled trials have been mixed. Here the investigators will explore whether active DBS in habenula for TRD will result in better symptom improvement than sham DBS. This study will ...

Phase N/A

tDCS as an add-on Treatment for Resistant Major Depression in Uni- or Bipolar Patients

The aim is to investigate the effect of transcranial Direct Current Stimulation (tDCS) applied at the anodal left CDLPF of patients with resistant depression compared to patients treated with conventional therapy. The tDCS is used in add-on drug treatment in resistant depression stabilized for 4 weeks (antidepressant as SSRIs (Selective ...


Placebo-controlled Trial of 5-hydroxytryptophan and Creatine for SSRI or SNRI Augmentation in Treatment Resistant Depression in Females

Serotonin and creatine are processed separately in the brain, and deficits in these brain biochemicals lead to distinct clinical problems. Therefore, investigators believe that treatment with a combination therapy, which could correct both deficits, would have a synergistic effect in the treatment of hypoxia-related depression and possibly other forms of ...


Clinical Trial on Efficacy of rTMS to Improve ECT in Treatment-Resistant Depression

Included patients are adults, aged between 18 and 70 years, with major depression (Hamilton Rating scale for Depression, HAMD 15). Patients don't have any experience concerning repeated Transcranial Magnetic Stimulation (rTMS). Patients with treatment-resistant depression (TRD) were assigned to two treatment groups in addition to their current pharmacotherapy regimen : ...

Phase N/A

Adjunct Minocyline in Treatment-resistant Depression

This is a double-blind, placebo-controlled, randomized, multicenter proof-of-principle trial of adjunctive minocycline for patients with unipolar major depressive disorder (MDD). The study tests the antidepressant efficacy of minocycline as an adjunct to an antidepressant standard treatment with es-/citalopram, venlafaxine or mirtazapine monotherapy (AD-ST), for patients with unipolar major depressive disorder ...


Cognitive Markers of Response to Treatment in Resistant Depression

Patients with depression are frequently treatment resistant. Clinical manifestations of depression are various, but cognitive dysfunctions are commonly present. Many factors are involved in treatment resistance. As no biological marker is available, clinical markers could be considered in predicting response to antidepressive treatment. The aim of this study is to ...

Phase N/A

Clinical Trial of the Use of Ketamine in Treatment Resistant Depression

The purpose of this study is to determine the efficacy of the use of intravenous low-dose ketamine (0.5 mg/kg) in the treatment of treatment-resistant depression (TRD), as well as the changes in Glutamate neurotransmission measured by Magnetic Resonance Imaging Spectroscopy and inflammatory serum markers (IL-6, TNF-alpha).


Focal Electrically Administered Seizure Therapy for the Treatment of Depression

Recurrent and treatment resistant depression (TRD) has high morbidity and escalating costs for the healthcare system and society at large. Electroconvulsive therapy (ECT) remains the most effective acute antidepressant treatment for TRD, but with significant risks of cognitive impairment. The efficacy and side effects of conventional ECT are contingent on ...

Phase N/A